RALEIGH, N.C. and DURHAM, N.C., July 22, 2019 /PRNewswire/ — Arbour Group LLC, a global provider of regulatory compliance services for the life sciences industry, has named industry executive Dominic Mancini as their new Vice President of Business Development. Dominic brings 16 plus years of experience in the biotech, pharma and medtech industries. His expertise expands across clinical services, product development and R&D intelligence, creating a vast network of service-oriented client relationships.
Mancini will be responsible for building Arbour’s footprint in the Raleigh-Durham biotech, pharma and medtech communities and beyond into the broader southeast market. “North Carolina is home to many emerging life science R&D innovators, pharmaceutical manufacturers, medical device and contract research organizations,” Mancini notes. “With over 20 years of global compliance experience, exceptional delivery performance and outstanding customer service, Arbour Group is prepared to support this region’s evolving life science software technology systems toward compliance with all applicable regulations.”
“I’m excited for Dominic to join the Arbour team,” said Ahsan Raza, President of Arbour Group. “His integrated business development, sales experience and scalable marketing methods will help us capitalize on the strength of Arbour products and services.” Arbour Group will be opening a Raleigh-Durham office to be located at the North Carolina Biotechnology Center in the Research Triangle Park. With Dominic’s local presence, this move will mark a notable presence for Arbour Group in support of planned growth strategies in NC.
Media Contact: Angelica Perez 3122075816 aperez@arbourgroup.com
Related Links
View original content:http://www.prnewswire.com/news-releases/arbour-group-expands-its-regulatory-compliance-footprint-in-research-triangle-park-300888359.html
SOURCE Arbour Group
In the newly-released educational guide What Is Rapé?, Sacred Connection covers essential topics around Rapé…
Accelerating platform-driven clinical innovation across vascular, neurovascular, and cardiovascular applications through a centralized Bionanomatrix™ IP…
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over…
SAN JOSE, CA / ACCESS Newswire / February 5, 2026 / VSEE Health, Inc. (NASDAQ:VSEE),…
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA…
ESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP)…